| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.VACCINE.2012.03.010 |
| P698 | PubMed publication ID | 22426327 |
| P2093 | author name string | Yan Liu | |
| Qiang Gao | |||
| Wei-Dong Yin | |||
| Yan-Ping Li | |||
| Jun-Zhi Wang | |||
| Shu-Qun Wen | |||
| Rong-Cheng Li | |||
| Qun-Ying Mao | |||
| Zheng-Lun Liang | |||
| Li-Rong Huang | |||
| P2860 | cites work | Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. | Q30356902 |
| Enterovirus 71 vaccine: close but still far. | Q33558268 | ||
| An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. | Q33875086 | ||
| Epidemiologic and virologic investigation of hand, foot, and mouth disease, southern Vietnam, 2005. | Q36034012 | ||
| Genetic evolution of enterovirus 71: epidemiological and pathological implications | Q36815002 | ||
| Seroepidemiology of human enterovirus 71, Singapore | Q37320284 | ||
| Virology, epidemiology, pathogenesis, and control of enterovirus 71. | Q37801742 | ||
| Enterovirus 71 virus-like particle vaccine: Improved production conditions for enhanced yield | Q39662972 | ||
| Enterovirus 71 outbreak, Brunei | Q39900119 | ||
| Deaths of children during an outbreak of hand, foot, and mouth disease in sarawak, malaysia: clinical and pathological characteristics of the disease. For the Outbreak Study Group | Q40614108 | ||
| Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease | Q41988715 | ||
| Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. | Q44566080 | ||
| Neutralizing antibodies to enterovirus 71 in Belém, Brazil | Q45193950 | ||
| Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus | Q45734536 | ||
| An apparently new enterovirus isolated from patients with disease of the central nervous system | Q46144493 | ||
| A randomized trial of alternative two- and three-dose hepatitis B vaccination regimens in adolescents: antibody responses, safety, and immunologic memory. | Q52019648 | ||
| Risk Factors of Enterovirus 71 Infection and Associated Hand, Foot, and Mouth Disease/Herpangina in Children During an Epidemic in Taiwan | Q56879053 | ||
| Establishing China's national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines | Q57096715 | ||
| Virological diagnosis of enterovirus type 71 infections: Experiences gained during an epidemic of acute CNS diseases in Hungary in 1978 | Q72939040 | ||
| An open study of subcutaneous administration of inactivated hepatitis A vaccine (VAQTA) in adults: safety, tolerability, and immunogenicity | Q74100892 | ||
| Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection | Q81196924 | ||
| Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection | Q84059759 | ||
| Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71 | Q85066827 | ||
| P433 | issue | 22 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vaccine | Q134808 |
| placebo | Q269829 | ||
| phase I clinical trial | Q5452194 | ||
| P304 | page(s) | 3295-3303 | |
| P577 | publication date | 2012-03-15 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial | |
| P478 | volume | 30 |
| Q42694361 | A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine |
| Q40153226 | A neonatal gnotobiotic pig model of human enterovirus 71 infection and associated immune responses |
| Q36363771 | A neonatal mouse model of coxsackievirus A16 for vaccine evaluation |
| Q33685512 | A novel universal neutralizing monoclonal antibody against enterovirus 71 that targets the highly conserved "knob" region of VP3 protein |
| Q46825689 | A safety study of inactivated Enterovirus 71 vaccine |
| Q92848842 | Advances in Vaccines |
| Q92968336 | An inactivated enterovirus 71 vaccine is safe and immunogenic in healthy adults: A phase I, double blind, randomized, placebo-controlled, study of two dosages |
| Q33724967 | An inactivated hand-foot-and-mouth disease vaccine using the enterovirus 71 (C4a) strain isolated from a Korean patient induces a strong immunogenic response in mice. |
| Q33806668 | Analysis of cross-reactive neutralizing antibodies in human HFMD serum with an EV71 pseudovirus-based assay |
| Q39255114 | Antigenic analysis of divergent genotypes human Enterovirus 71 viruses by a panel of neutralizing monoclonal antibodies: current genotyping of EV71 does not reflect their antigenicity. |
| Q35689929 | Broad protection with an inactivated vaccine against primary-isolated lethal enterovirus 71 infection in newborn mice |
| Q34406820 | Challenges to licensure of enterovirus 71 vaccines |
| Q36978457 | Characterization of the enterovirus 71 P1 polyprotein expressed in Pichia pastor as a candidate vaccine |
| Q42204996 | Characterization of the enterovirus 71 VP1 protein as a vaccine candidate |
| Q37303819 | Children of rural-to-urban migrant workers in China are at a higher risk of contracting severe hand, foot and mouth disease and EV71 infection: a hospital-based study |
| Q34430681 | Comparative analysis of the immunogenicity and protective effects of inactivated EV71 vaccines in mice |
| Q37130763 | Comprehensive safety assessment of a human inactivated diploid enterovirus 71 vaccine based on a phase III clinical trial |
| Q33701681 | Concentration and purification of enterovirus 71 using a weak anion-exchange monolithic column |
| Q26828723 | Considerations for developing an immunization strategy with enterovirus 71 vaccine |
| Q33887710 | Cryo-electron microscopy study of insect cell-expressed enterovirus 71 and coxsackievirus a16 virus-like particles provides a structural basis for vaccine development |
| Q40889243 | Determinants of EV71 immunogenicity and protection against lethal challenge in a mouse model |
| Q37681184 | Development of a sandwich ELISA for the quantification of enterovirus 71. |
| Q30383172 | EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD). |
| Q34540559 | EV71 vaccine, an invaluable gift for children |
| Q92374884 | Effectiveness of EV-A71 vaccination in prevention of paediatric hand, foot, and mouth disease associated with EV-A71 virus infection requiring hospitalisation in Henan, China, 2017-18: a test-negative case-control study |
| Q57049727 | Enhanced neutralizing antibody response induced by inactivated enterovirus 71 in cynomolgus monkeys |
| Q38919967 | Enhancing enterovirus A71 vaccine production yield by microcarrier profusion bioreactor culture |
| Q38840182 | Enterovirus 71: a whole virion inactivated enterovirus 71 vaccine |
| Q64138183 | Five-year immunity persistence following immunization with inactivated enterovirus 71 type (EV71) vaccine in healthy children: A further observation |
| Q35053266 | Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers |
| Q38404281 | Global quantitative proteomic analysis of human glioma cells profiled host protein expression in response to enterovirus type 71 infection |
| Q34033907 | How to understand the efficacy measurements for enterovirus type 71 vaccine? |
| Q43434704 | Immune responses to baculovirus-displayed enterovirus 71 VP1 antigen |
| Q34324574 | Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial |
| Q37469307 | Immunogenicity, safety, and lot consistency of a novel inactivated enterovirus 71 vaccine in Chinese children aged 6 to 59 months |
| Q28485432 | Immunological and biochemical characterization of coxsackie virus A16 viral particles |
| Q47145137 | Immunopathogenesis and Virus-Host Interactions of Enterovirus 71 in Patients with Hand, Foot and Mouth Disease |
| Q30382068 | Implications of Age-Dependent Immune Responses to Enterovirus 71 Infection for Disease Pathogenesis and Vaccine Design. |
| Q54247724 | Induction of a high-titered antibody response using HIV gag-EV71 VP1-based virus-like particles with the capacity to protect newborn mice challenged with a lethal dose of enterovirus 71. |
| Q89752168 | Interchangeability of two Enterovirus 71 inactivated vaccines in Chinese children: A phase IV, open-label, and randomized controlled trial |
| Q40174785 | Intradermal injection of a fractional dose of an inactivated HFMD vaccine elicits similar protective immunity to intramuscular inoculation of a full dose of an Al(OH)3-adjuvanted vaccine |
| Q34149853 | Long-term immunogenicity studies of formalin-inactivated enterovirus 71 whole-virion vaccine in macaques |
| Q39350594 | Mouse adaptation of a sub-genogroup B5 strain of human enterovirus 71 is associated with a novel lysine to glutamic acid substitution at position 244 in protein VP1. |
| Q42254889 | Preclinical evaluation of the immunogenicity and safety of an inactivated enterovirus 71 candidate vaccine |
| Q26866091 | Production of EV71 vaccine candidates |
| Q38068107 | Progress on the research and development of human enterovirus 71 (EV71) vaccines |
| Q37530094 | Progress on the research and development of inactivated EV71 whole-virus vaccines |
| Q90227538 | Safety and immunogenicity of an experimental live combination vaccine against enterovirus 71 and coxsackievirus A16 in rhesus monkeys |
| Q102216661 | Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial |
| Q34820250 | Seroepidemiology of human enterovirus71 and coxsackievirusA16 among children in Guangdong province, China |
| Q36479953 | Seroprevalence of Enterovirus 71 Antibody Among Children in China: A Systematic Review and Meta-analysis. |
| Q36734771 | Strategies to develop antivirals against enterovirus 71 |
| Q42230193 | Surveillance of hand, foot, and mouth disease for a vaccine |
| Q36389012 | The compatibility of inactivated-Enterovirus 71 vaccination with Coxsackievirus A16 and Poliovirus immunizations in humans and animals |
| Q35048558 | The cross-neutralizing activity of enterovirus 71 subgenotype c4 vaccines in healthy chinese infants and children |
| Q28080796 | Therapeutic and prevention strategies against human enterovirus 71 infection |
| Q40955592 | Two-year efficacy and immunogenicity of Sinovac Enterovirus 71 vaccine against hand, foot and mouth disease in children |
| Q38192021 | Update of enterovirus 71 infection: epidemiology, pathogenesis and vaccine |
| Q38225695 | Update on the development of enterovirus 71 vaccines |
Search more.